Chester County News and Community Website
PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) announced it has granted stock options to purchase 30,000 shares of common stock to a newly hired employee as part of an …
Context Therapeutics Grants Stock Options to New Hire Read More PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) announced that it will participate in two major investor conferences in September.
Context Therapeutics to Present at Upcoming Investor Conferences Read More PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX), a clinical-stage biotechnology company advancing T cell-engaging bispecific antibodies for solid tumors, reported a second-quarter net loss of $8.8 million as it continues …
Context Therapeutics Highlights Pipeline Progress, Reports $8.8M Loss in Q2 Read More PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) has announced the appointment of Dr. Karen Chagin, M.D. as Chief Medical Officer (CMO), effective June 9, 2025. Dr. Chagin will succeed …
Context Therapeutics Names Dr. Karen Chagin as Chief Medical Officer Read More PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) announced it has granted stock options to purchase a total of 160,000 shares of common stock to two new employees as an …
Context Therapeutics Grants Stock Options to New Hires as Part of Strategic Talent Growth Read More PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) has announced financial results for the first quarter ended March 31, 2025, alongside updates on its clinical pipeline and leadership. The company …
Context Therapeutics Reports Q1 2025 Financial Results and Clinical Progress Read More PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) has announced the appointment of Dr. Karen Smith, MD, PhD, MBA, LLM, as interim Chief Medical Officer (CMO), effective May 10, 2025. …
Context Therapeutics Names Dr. Karen Smith as Interim Chief Medical Officer Read More PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) presented preclinical and translational data on its clinical asset, CT-95, at the 2025 American Association for Cancer Research (AACR) Annual Meeting. The …
Context Therapeutics Showcases Promising CT-95 Data at AACR Annual Meeting Read More PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) has announced the dosing of the first patient in its Phase 1 clinical trial of CT-95, a bispecific antibody designed to target …
Context Therapeutics Begins Phase 1 Trial of CT-95 Targeting Mesothelin-Expressing Cancers Read More PHILADELPHIA, PA — Context Therapeutics Inc. has confirmed its presence at several prominent investor conferences scheduled over the coming months. The company will update investors on its innovative pipeline, including …
Context Therapeutics Announces Participation in Key Investor Conferences Read More